블랙스톤, '라이프사이언스 6호 펀드' 63억 달러로 클로징…하드캡 달성

Blackstone's record-breaking $6.3 billion Life Sciences Fund closure reflects surging institutional investor confidence in healthcare innovation and signals a major expansion of capital flowing into pharmaceutical development and medical technology advances. The fund's hard cap achievement demonstrates how major private equity firms are becoming essential drivers of drug development, with Blackstone supporting over 215 medicines and securing 34 regulatory approvals globally. This trend indicates that institutional capital is increasingly concentrated in life sciences as investors recognize the critical role these innovations play in transforming patient outcomes and addressing healthcare needs.